IL1B and COVID-19: Wu and Yan (66) suggest that in COVID-19 patients the FDA approved JAK2 inhibitor Fedratinib, in combination with anti-viral drugs, could be used to reduce the mortality associated with hyperinflammation by suppressing the production of several Th17 cytokines (i.e., IL1b and TNFalpha, IL21, IL22, IL17) and the formation of pulmonary edema.